Citadel Advisors
TVRD

Citadel Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Citadel Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,266
Closed -$11.8K – 15482
2024
Q2 		$11.8K Buy
+1,266
New +$30.2K ﹤0.01% 13017
2024
Q1 		– Sell
-2,382
Closed -$63.7K – 15603
2023
Q4 		$63.7K Buy
2,382
+1,293
+119% +$53.5K ﹤0.01% 11515
2023
Q3 		$65.8K Sell
1,089
-6,363
-85% -$597K ﹤0.01% 11404
2023
Q2 		$759K Sell
7,452
-5,953
-44% -$820K ﹤0.01% 7031
2023
Q1 		$2.37M Buy
13,405
+10,542
+368% +$3.53M ﹤0.01% 5036
2022
Q4 		$1.11M Buy
2,863
+217
+8% +$82.4K ﹤0.01% 6618
2022
Q3 		$892K Sell
2,646
-4,460
-63% -$1.62M ﹤0.01% 7238
2022
Q2 		$2.34M Buy
7,106
+1,140
+19% +$400K ﹤0.01% 5243
2022
Q1 		$2.61M Buy
5,966
+5,576
+1,430% +$2.29M ﹤0.01% 5491
2021
Q4 		$171K Sell
390
-1,904
-83% -$957K ﹤0.01% 12092
2021
Q3 		$1.28M Buy
2,294
+1,010
+79% +$507K ﹤0.01% 7508
2021
Q2 		$660K Sell
1,284
-4,745
-79% -$3.01M ﹤0.01% 9382
2021
Q1 		$4.71M Buy
6,029
+692
+13% +$474K ﹤0.01% 4382
2020
Q4 		$2.91M Buy
5,337
+2,832
+113% +$1.48M ﹤0.01% 4634
2020
Q3 		$1.15M Buy
2,505
+1,677
+203% +$974K ﹤0.01% 5784
2020
Q2 		$510K Buy
+828
New +$457K ﹤0.01% 7035
2020
Q1 		– Sell
-1,282
Closed -$697K – 10316
2019
Q4 		$744K Sell
1,282
-10,513
-89% -$7.38M ﹤0.01% 6134
2019
Q3 		$7.76M Buy
11,795
+2,647
+29% +$2.2M ﹤0.01% 2538
2019
Q2 		$7.08M Buy
9,148
+333
+4% +$234K ﹤0.01% 2612
2019
Q1 		$6.23M Buy
8,815
+7,440
+541% +$4.45M ﹤0.01% 2684
2018
Q4 		$644K Buy
1,375
+255
+23% +$164K ﹤0.01% 6008
2018
Q3 		$965K Sell
1,120
-1,035
-48% -$747K ﹤0.01% 5621
2018
Q2 		$1.49M Hold
2,155
– – ﹤0.01% 4558
2018
Q1 		$960K Hold
2,155
– – ﹤0.01% 4871
2017
Q4 		$949K Hold
2,155
– – ﹤0.01% 4727
2017
Q3 		$1.06M Sell
2,155
-363
-14% -$182K ﹤0.01% 4240
2017
Q2 		$1.4M Buy
2,518
+1,122
+80% +$712K ﹤0.01% 3628
2017
Q1 		$924K Buy
1,396
+1,072
+331% +$573K ﹤0.01% 4120
2016
Q4 		$108K Sell
324
-292
-47% -$93.7K ﹤0.01% 6642
2016
Q3 		$185K Buy
+616
New +$133K ﹤0.01% 6351
2016
Q1 		– Sell
-2,556
Closed -$1.55M – 8155
2015
Q4 		$1.55M Buy
2,556
+871
+52% +$478K ﹤0.01% 3032
2015
Q3 		$867K Buy
+1,685
New +$1.13M ﹤0.01% 4004

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Citadel Advisors's TVRD Position: Q3 2024 in Review

Citadel Advisors sold out of Tvardi Therapeutics (TVRD) in Q3 2024, closing a stake of 1,266 shares — an estimated $11.8K sold.

Citadel Advisors first reported a position in TVRD in Q3 2015 and held it in 32 quarters. The position peaked at $7.76M in Q3 2019. 69 funds tracked by Wall St. Rank hold TVRD as of Q3 2024.

  • Citadel Advisors reported no remaining Tvardi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 1,266 Tvardi Therapeutics shares in Q3 2024, an estimated $11.8K.
  • Citadel Advisors first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 32 quarters.
  • Citadel Advisors's Tvardi Therapeutics position peaked at $7.76M in Q3 2019.
  • 69 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.